The transaction is expected to close on or about July 22, 2009, subject to the satisfaction of customary closing conditions. The offering will result in gross proceeds of $15 million to Electro-Optical Sciences (EOS), before deducting placement agents' fees and estimated offering expenses.
EOS intends to use the net proceeds from the sale of the shares to fund pursuit of its pre-market approval application for MelaFind, the continued development and, if and when approved by the FDA, the commercialization of MelaFind, and for general corporate purposes, including working capital.
Needham & Company served as the lead placement agent and Oppenheimer & Co served as the co-placement agent for the offering.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index